Eli Lilly reports 1% Q4 decline from Zyprexa patent expiration
INDIANAPOLIS — Eli Lilly and Company on Tuesday reported that its fourth quarter revenue for the period ended Dec. 31 declined 1% to $6 billion because of its Zyprexa patent expiration. Full-year 2012 revenue declined 7% to $22.6 billion.
"Lilly delivered solid financial results in the fourth quarter of 2012, as we successfully offset a large part of the revenue decline from the Zyprexa patent expiration with growth in other products such as Cymbalta, Forteo, Alimta, Effient and our animal health portfolio," stated John Lechleiter, Lilly’s chairman, president and CEO. "At the same time, we continued to control costs while investing in R&D in order to replenish and advance our pipeline. Today, Lilly has 13 potential new medicines in Phase III testing. We are well-positioned to deliver on our innovation-based strategy and create long-term value for all of our stakeholders."
Find us on Facebook for even more insight, analysis and the latest in drug store news.
New York Times: Battle against biogenerics is on
NEW YORK — The battle against biogenerics is on, noted a report published in The New York Times Tuesday. As many as eight states have introduced legislation that would restrict generic competition of biological pharamceuticals so far this year and one, the Virginia House of Delegates, already passed such a measure by a 91-to-6 vote.
At the federal level biological manufactures are squaring off against their potential generic competitors on whether or not the generic equivalent can share the same generic name as the brand product, the NYT report noted. If no, then pharmacists will be unable to substitute one for the other even if a state were to allow biogenerics.
Sanofi’s Auvi-Q epinephrine injection now available
BRIDGEWATER, N.J. — Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.
Auvi-Q is the first-and-only epinephrine auto-injector with audio and visual cues for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The size and shape of a credit card and the thickness of a smart phone, Auvi-Q is a breakthrough in epinephrine auto-injector device design that talks patients and caregivers step-by-step through the injection process.
“Patient feedback was a critical component to the development process for Auvi-Q,” said Anne Whitaker, president of North America Pharmaceuticals, Sanofi. “The availability of Auvi-Q represents an important step forward in our continued innovation to meet the needs of people at risk for anaphylaxis and their caregivers.”
Up to six million Americans may be at risk for anaphylaxis, although the precise incidence is unknown and may be underreported. While guidelines emphasize the importance of the life-saving role of epinephrine, recent surveys show that two-thirds of patients and caregivers do not carry their epinephrine auto-injectors as recommended, and nearly half worry that others will not know how to use their or their child’s epinephrine auto-injector correctly during an emergency. Multiple studies have found an association between delay in epinephrine administration and death from anaphylaxis.